CCADD members attended the 2024 Fall Conference of the Korean Society for Clinical Pharmacology and Therapeutics (KSCPT), which was held from November 13th to 15th at Kim Dae-jung Convention Center in Gwangju.

The conference was organized around the theme "Clinical Pharmacology in Innovative Therapeutics" and featured various sessions on latest topics, including Live Biotherapeutic Products, ICT in Clinical Trials, Voice from the Clinical Trial Field, Innovative Sites for Early Phase Clinical Trials, Omics with Clinical Pharmacology, and GCP Updates.

In the Live Biotherapeutic Products session, insights were shared on the discovery, CMC, non-clinical, and clinical studies of microbiome therapeutics, a promising new treatment modality. The ICT in Clinical Trials session addressed the latest developments in Real-World Evidence-based clinical trials and Decentralized Clinical Trials.The Voice from the Clinical Trial Field session brought together experts from institutions, SMOs, CROs, and clinical trial sites to share practical insights.

More importantly, CCADD members introduced their works through poster presentations. 

David Seung U Lee, as the lead presenter, introduced the study "Improving Few-Shot Performance of Large Language Models to Extract Clinical Information from Real-World Clinical Notes." This research evaluated how large language models (LLMs) like Llama-3.18 perform on clinical information extraction tasks using annotated notes from Seoul National University Hospital. The study demonstrated the importance of optimized prompting strategies and entity distributions, achieving high accuracy and robustness. These findings highlight the potential of LLMs in advancing clinical text analysis for real-world applications. Meanwhile Jung-Hyu Won and Yun Jin Choi presented their study titled "Comparing the Therapeutic Efficacy of Tisagenlecleucel and Salvage Chemotherapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A MAIC Approach." This research retrospectively analyzed outcomes using the Matching-Adjusted Indirect Comparison (MAIC) method to evaluate Tisagenlecleucel, a CD19-targeting CAR-T cell therapy, against salvage/reinduction chemotherapy. Results showed that while no significant differences were observed in overall remission rates (ORR) or overall survival (OS), Tisagenlecleucel achieved a significantly higher complete remission (CR) rate. These findings highlight the potential of CAR-T therapy as an effective option for pediatric relapsed/refractory B-ALL.

Through their participation in this conference, CCADD members gained a deeper understanding of the latest advancements in clinical pharmacology and therapeutics.